Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 3
1974 3
1975 9
1976 12
1977 43
1978 35
1979 28
1980 55
1981 44
1982 47
1983 58
1984 75
1985 74
1986 65
1987 66
1988 54
1989 63
1990 53
1991 71
1992 67
1993 54
1994 33
1995 42
1996 27
1997 36
1998 38
1999 38
2000 44
2001 38
2002 42
2003 39
2004 42
2005 43
2006 41
2007 43
2008 35
2009 35
2010 40
2011 30
2012 43
2013 41
2014 31
2015 39
2016 37
2017 42
2018 35
2019 41
2020 51
2021 53
2022 44
2023 45
2024 48
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,132 results

Results by year

Filters applied: . Clear all
Page 1
Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality.
Olleik F, Kamareddine MH, Spears J, Tse G, Liu T, Yan GX. Olleik F, et al. Pacing Clin Electrophysiol. 2023 Nov;46(11):1348-1356. doi: 10.1111/pace.14846. Epub 2023 Oct 17. Pacing Clin Electrophysiol. 2023. PMID: 37846818 Review.
Mexiletine, a class Ib antiarrhythmic drug, exhibits its major antiarrhythmic effect via inhibition of the fast and late Na(+) currents in myocardial tissues that are dependent on the opening of Na(+) channels for their excitation. Through a comprehensive examination of …
Mexiletine, a class Ib antiarrhythmic drug, exhibits its major antiarrhythmic effect via inhibition of the fast and late Na(+) curren …
About the different faces of mexiletine.
Postema PG. Postema PG. Heart Rhythm. 2020 Nov;17(11):1951-1952. doi: 10.1016/j.hrthm.2020.06.013. Epub 2020 Jun 13. Heart Rhythm. 2020. PMID: 32544436 No abstract available.
Mexiletine metabolites: a review.
Catalano A, Carocci A, Sinicropi MS. Catalano A, et al. Curr Med Chem. 2015;22(11):1400-13. doi: 10.2174/0929867322666150227145412. Curr Med Chem. 2015. PMID: 25723511 Review.
Mexiletine belongs to class IB antiarrhythmic drugs and it is still considered a drug of choice for treating myotonias. ...Mexiletine is extensive metabolized in humans via phase I and phase II reactions. Only a small fraction (about 10%) of the dose of mexiletin …
Mexiletine belongs to class IB antiarrhythmic drugs and it is still considered a drug of choice for treating myotonias. ...Mexilet …
Mexiletine.
Campbell RW. Campbell RW. N Engl J Med. 1987 Jan 1;316(1):29-34. doi: 10.1056/NEJM198701013160106. N Engl J Med. 1987. PMID: 3537793 Review. No abstract available.
Mexiletine in Myotonic Dystrophy Type 1: A Randomized, Double-Blind, Placebo-Controlled Trial.
Heatwole C, Luebbe E, Rosero S, Eichinger K, Martens W, Hilbert J, Dekdebrun J, Dilek N, Zizzi C, Johnson N, Puwanant A, Tawil R, Schifitto G, Beck CA, Richeson JF, Zareba W, Thornton C, McDermott MP, Moxley R 3rd. Heatwole C, et al. Neurology. 2021 Jan 12;96(2):e228-e240. doi: 10.1212/WNL.0000000000011002. Epub 2020 Oct 12. Neurology. 2021. PMID: 33046619 Free PMC article. Clinical Trial.
OBJECTIVE: To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients with myotonic dystrophy type 1 (DM1). ...There were no differences between the mexiletine and placebo groups with respect to the frequ …
OBJECTIVE: To assess mexiletine's long-term safety and effect on 6-minute walk distance in a well-defined cohort of patients w …
Mexiletine: pharmacology and therapeutic use.
Manolis AS, Deering TF, Cameron J, Estes NA 3rd. Manolis AS, et al. Clin Cardiol. 1990 May;13(5):349-59. doi: 10.1002/clc.4960130509. Clin Cardiol. 1990. PMID: 2189614 Free article. Review.
Mexiletine is a Class IB antiarrhythmic which has basic and clinical electrophysiologic properties similar to lidocaine. Like other Class I antiarrhythmic agents, mexiletine blocks the rapid inward sodium current responsible for phase 0 of the action potential. ...
Mexiletine is a Class IB antiarrhythmic which has basic and clinical electrophysiologic properties similar to lidocaine. Like other C …
Mexiletine: a new type I antiarrhythmic agent.
Schrader BJ, Bauman JL. Schrader BJ, et al. Drug Intell Clin Pharm. 1986 Apr;20(4):255-60. doi: 10.1177/106002808602000401. Drug Intell Clin Pharm. 1986. PMID: 2421992 Review.
Mexiletine is a type I antiarrhythmic drug that is structurally similar to lidocaine. Mexiletine has considerable potential for causing neurologic, cardiac, or gastrointestinal side effects. ...Efficacy and toxicity are not well correlated with mexiletine ser …
Mexiletine is a type I antiarrhythmic drug that is structurally similar to lidocaine. Mexiletine has considerable potential fo …
Relevance of mexiletine in the era of evolving antiarrhythmic therapy of ventricular arrhythmias.
Alhourani N, Wolfes J, Könemann H, Ellermann C, Frommeyer G, Güner F, Lange PS, Reinke F, Köbe J, Eckardt L. Alhourani N, et al. Clin Res Cardiol. 2024 Jun;113(6):791-800. doi: 10.1007/s00392-024-02383-9. Epub 2024 Feb 14. Clin Res Cardiol. 2024. PMID: 38353682 Free PMC article. Review.
Nevertheless, certain patients with structural heart disease suffering from drug-refractory, i.e., mainly amiodarone refractory ventricular arrhythmias, as well as those with selected forms of congenital long QT syndrome (LQTS) may nowadays still benefit from mexiletine. H …
Nevertheless, certain patients with structural heart disease suffering from drug-refractory, i.e., mainly amiodarone refractory ventricular …
Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.
Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kishimoto Y, Kinoshita F, Hirakawa A, Shimizu S, Nakamura T, Katsuno M. Yamada S, et al. Ann Clin Transl Neurol. 2022 Nov;9(11):1702-1714. doi: 10.1002/acn3.51667. Epub 2022 Oct 8. Ann Clin Transl Neurol. 2022. PMID: 36208052 Free PMC article. Clinical Trial.
In the MEXPRESS trial, 20 participants took mexiletine or lactose, three times a day for 4 weeks with a crossover design. There was no difference in distal latencies at room temperature and under cold exposure between mexiletine and placebo groups as the primary end …
In the MEXPRESS trial, 20 participants took mexiletine or lactose, three times a day for 4 weeks with a crossover design. There was n …
Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.
Jarvis B, Coukell AJ. Jarvis B, et al. Drugs. 1998 Oct;56(4):691-707. doi: 10.2165/00003495-199856040-00016. Drugs. 1998. PMID: 9806111 Review.
EMs, but not PMs, are susceptible to drug interactions between mexiletine and drugs that inhibit CYP2D6 (e.g. quinidine). Moreover, mexiletine inhibits CYP2D6-mediated metabolism of metoprolol and cytochrome P450 1A2-mediated metabolism of theophylline. Phenytoin an …
EMs, but not PMs, are susceptible to drug interactions between mexiletine and drugs that inhibit CYP2D6 (e.g. quinidine). Moreover, …
2,132 results